SOPHiA GENETICS SA (SOPH)
| Previous Close | 5.06 |
| Open | 5.13 |
| Bid | 3.64 x 200 |
| Ask | 6.47 x 200 |
| Day's Range | 4.96 - 5.13 |
| 52 Week Range | 2.13 - 7.37 |
| Volume | |
| Avg. Volume | 59,622 |
| Market Cap | 329.119M |
| Beta (5Y Monthly) | 1.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024
BOSTON and ROLLE, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced it will release its financial results for the first quarter of fiscal year 2024 before U.S. markets open on Tuesday, May 7, 2024. On that day, SOPHiA GENETICS will host a conference call to discuss its financial results as well as business outlook beginning at 8:00 a.m. (08:00) EDT / 2:00 p.m. (14:00) CET. The call will be webcas
- PR Newswire
SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that Nigeria-based Syndicate Bio has signed on to implement MSK-ACCESS® powered with SOPHiA DDM™. Syndicate Bio is the first lab in Africa to adopt the MSK-ACCESS® assay via the SOPHiA DDM™ Platform, and the first company to make comprehensive genomic profiling and liquid biopsy widely available to patients throughout the entire continent. The implementati
- PR Newswire
SOPHiA GENETICS Announces Unilabs is using its AI Technology to Detect Homologous Recombination Deficiency (HRD)
SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced that Unilabs, one of the largest diagnostic providers in Europe, and the only provider to offer laboratory, imaging and pathology specialties within one group, is live on the SOPHiA DDM™ Platform. Unilabs will use SOPHiA GENETICS' technology to test for HRD-status in solid tumors and provide expedited analysis across its network in Switzerland.
